Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity Program
Pfizer announced a strategic co-funding agreement with Blackstone Life Sciences to secure up to $1.5 billion to advance berobenatide, its investigational monthly GLP-1 receptor agonist for obesity treatment. The funding will support 10 planned Phase III studies through 2028, with Pfizer retaining full control of the program. Blackstone will receive milestone-based payments tied to regulatory approval and commercial sales milestones.
